Profile data is unavailable for this security.
About the company
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.
- Revenue in USD (TTM)57.42m
- Net income in USD-55.19m
- Incorporated2013
- Employees99.00
- LocationTheravance Biopharma IncUGLAND HOUSE, SOUTH CHURCH STREETGEORGE TOWN KY1-1104Cayman IslandsCYM
- Phone+1 3456 508086000
- Websitehttps://www.theravance.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cartesian Therapeutics Inc | 26.00m | -219.71m | 392.76m | 38.00 | -- | -- | -- | 15.10 | -41.77 | -41.77 | 5.03 | -25.87 | 0.1104 | -- | 4.17 | 684,315.80 | -93.31 | -43.66 | -116.36 | -66.84 | -- | -- | -844.91 | -136.35 | -- | -0.5814 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| PepGen Inc | 0.00 | -78.63m | 397.31m | 64.00 | -- | 2.70 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Entrada Therapeutics Inc | 129.01m | -6.69m | 398.17m | 159.00 | -- | 1.63 | -- | 3.09 | -0.2543 | -0.2543 | 3.86 | 7.25 | 0.3578 | -- | -- | 811,402.50 | -1.85 | -- | -2.47 | -- | -- | -- | -5.18 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| OraSure Technologies, Inc. | 405.47m | 53.66m | 404.74m | 638.00 | 7.34 | 0.9032 | 5.43 | 0.9982 | 0.7204 | 0.7204 | 5.47 | 5.86 | 0.8748 | 3.15 | 7.31 | 635,536.10 | 11.58 | 0.7238 | 13.11 | 0.8212 | 44.25 | 46.94 | 13.23 | 1.13 | 8.57 | -- | 0.0018 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
| Lenz Therapeutics Inc | 0.00 | -124.65m | 405.23m | 6.00 | -- | 0.7164 | -- | -- | -15.35 | -15.35 | 0.00 | 22.15 | 0.00 | -- | -- | 0.00 | -48.85 | -- | -50.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| Tourmaline Bio Inc | 0.00 | -42.12m | 405.98m | 44.00 | -- | 1.57 | -- | -- | -10.18 | -10.18 | 0.00 | 10.08 | 0.00 | -- | -- | 0.00 | -20.85 | -- | -21.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Contineum Therapeutics Inc | 50.00m | 22.72m | 408.13m | 31.00 | 17.26 | -- | 17.78 | 8.16 | 0.9041 | 0.9041 | 1.99 | 4.96 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 45.44 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Theravance Biopharma Inc | 57.42m | -55.19m | 409.85m | 99.00 | -- | 1.91 | -- | 7.14 | -0.9704 | -0.9704 | 1.04 | 4.43 | 0.1161 | -- | 3.35 | 580,040.40 | -11.16 | -40.51 | -11.79 | -48.50 | -- | -- | -96.11 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Lexeo Therapeutics Inc | 0.00 | -66.39m | 410.20m | 58.00 | -- | 2.92 | -- | -- | -2.69 | -2.69 | 0.00 | 4.26 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0153 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| ACELYRIN Inc | 0.00 | -381.64m | 413.46m | 130.00 | -- | 0.6233 | -- | -- | -10.84 | -10.84 | 0.00 | 6.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Annexon Inc | 0.00 | -134.24m | 414.69m | 71.00 | -- | 1.42 | -- | -- | -1.78 | -1.78 | 0.00 | 3.20 | 0.00 | -- | -- | 0.00 | -46.07 | -44.06 | -49.49 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Alto Neuroscience Inc | 0.00 | -36.31m | 416.97m | 63.00 | -- | -- | -- | -- | -1.42 | -1.42 | 0.00 | 2.73 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.1238 | -- | -- | -- | -31.02 | -- | -- | -- |
| Travere Therapeutics Inc | 145.24m | -376.33m | 420.88m | 380.00 | -- | 2.08 | -- | 2.90 | -4.98 | -1.50 | 1.96 | 2.66 | 0.1988 | 1.40 | 7.68 | 382,205.30 | -51.50 | -36.95 | -65.94 | -44.77 | 92.12 | 95.92 | -259.11 | -165.79 | 3.41 | -- | 0.6526 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Cibus Inc | 1.82m | -267.63m | 422.25m | 183.00 | -- | 1.19 | -- | 232.39 | -22.63 | -22.63 | 0.1769 | 14.27 | 0.0064 | -- | -- | 9,928.96 | -119.13 | -86.28 | -135.32 | -96.45 | 2.31 | -- | -18,582.22 | -792.07 | -- | -3.70 | 0.0049 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
| Voyager Therapeutics Inc | 250.01m | 132.33m | 424.63m | 162.00 | 2.64 | 1.46 | 3.10 | 1.70 | 2.96 | 2.96 | 5.56 | 5.37 | 0.9792 | -- | 5.97 | 1,543,259.00 | 51.83 | 0.6378 | 70.85 | 0.8203 | -- | -- | 52.93 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Data as of May 01 2024. Currency figures normalised to Theravance Biopharma Inc's reporting currency: US Dollar USD
79.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Weiss Asset Management LPas of 01 Mar 2024 | 7.46m | 15.48% |
| The Baupost Group LLCas of 31 Dec 2023 | 7.42m | 15.40% |
| Madison Avenue Partners LPas of 31 Dec 2023 | 7.01m | 14.56% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 3.98m | 8.26% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 3.42m | 7.09% |
| Irenic Capital Management LPas of 31 Dec 2023 | 2.76m | 5.73% |
| Pictet Asset Management SAas of 31 Dec 2023 | 2.17m | 4.50% |
| Newtyn Management LLCas of 31 Dec 2023 | 1.90m | 3.95% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.39m | 2.89% |
| Oasis Management (Hong Kong) LLCas of 31 Dec 2023 | 1.01m | 2.09% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
